TNFSF11 and Miyoshi myopathy: In contrast, group 3 (MM) cases systematically showed increased -median (range)- levels of IL6 −41 (13–444) pg/mL-, BALP −656 (367–4201) ng/mL- and RANKL −1497 (841–4246) pg/mL- when compared with both group 1 −2.3 (0–22) pg/mL (p = 0.0001), 170 (29–316) ng/mL (p = 0.0001) and 533 (109–1082) pg/mL (p = 0.0001), respectively- and group 2 cases −3 (0.1–12) pg/mL (p = 0.0007), 245 (159–408) ng/mL (p = 0.005) and 737 (434–858) pg/mL (p = 0.001), respectively- (Figure 5).